Objective: Bevacizumab (avastin) is a recombinant human monoclonal IgG1 antibody for vascular endothelial growth factor (VEGF), and it shows an antitumor effect by inhibition of tumor angiogenesis. This study is to evaluate the effect of bevacizumab plus chemotherapy on advanced gastric cancer, and observe the safety in the meanwhile. Methods: Twelve patients with advanced gastric cancer confirmed clearly by histopathology received bevacizumab plus chemotherapy. The dose of bvacizumab was 7.5 mg/kg at Day 1, with a 21-day cycle, efficacy evaluation for every 2 cycles. Results: Efficacy was evaluated and side effect was observed in 12 patients. Of the patients, a first-line regimen was used in 5 patients and a second-line regimen was used in 7 patients. According to the standard of response evaluation criteria in solid tumors (RECIST), the results were as follows: No patients with complete remission, 8 partial remission, 3 stable remission, and 1 progression disease. The objective response rate was 67% and the disease control rate was 91%. The median progression-free survival time (mPFS) was 5.5 months and the median overall survival (mOS) was 7.0 months. Six patients had bone marrow suppression, 3 liver injury, 2 gastrointestinal reactions, and 1 hypertension, in which all toxicities were Grade I–II and all adverse reactions recovered after symptomatic treatment. No serious accident was occurred. Conclusion: The regimen of bevacizumab plus chemotherapy can well improve the response rate for advanced gastric cancer, and side reactions can be tolerated by patients.